Pladienolide pyridine compounds and methods of use

US9481669B2 · kind B2 · utility

Assignee

• Eisai R&D Management Co., Ltd. · JP

Inventors

• Gregg F. Keaney · Lexington, US
• John Wang · Andover, US
• Baudouin Gérard · Belmont, US
• Kenzo Arai · Ibaraki, JP
• Xiang LIU · Winchester, US
• Guo Zhu Zheng · Lexington, US
• Kazunobu Kira · Tsukuba, JP
• Parcharee Tivitmahaisoon · San Francisco, US
• Sudeep Prajapati · Somerville, US
• Nicholas C. Gearhart · Durango, US
• Yoshihiko Kotake · Ibaraki, JP
• Satoshi Nagao · Tsukuba, JP
• Regina Mikie Kanada Sonobe · Ibaraki, JP
• Masayuki Miyano · Tsukubamirai, JP
• Norio Murai
• Silvia Buonamici · Boston, US
• Lihua Yu · Acton, US
• Eunice Sun Park · Arlington, US
• Betty Chan · Harvard, US
• Peter Smith · Arlington, US
• Michael Thomas · Weisenheim am Berg, DE
• Ermira Pazolli · Wayland, US
• Kian Huat Lim · Burlington, US

Key dates

• Filing date: May 13, 2015
• Grant date: Nov 1, 2016
• Expiry date: May 13, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/06
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides novel pladienolide pyridine compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.